Breast Cancer

Breast Cancer

Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease

Scientists investigated the utility of the Oncomine Breast cfDNA Assay for detecting ctDNA in women from a breast screening population...

Journal of Clinical Oncology
Neoadjuvant Regimens Best Standard Care in HER2+ Breast Cancer

Two neoadjuvant treatment regimens can improve pCR rates over standard care in patients with HER2-positive breast cancer, according to phase 2 results published in Nature Communications.

Cancer Therapy Advisor
Men and Women Differ in Their Refusal of Breast Cancer Treatments

Women with breast cancer are more likely than their male counterparts to refuse hormone therapy or surgery, according to a retrospective study published in Clinical Breast Cancer.

Cancer Therapy Advisor

A Phase II Study of Talimogene Laherparepvec for Patients With Inoperable Locoregional Recurrence of Breast Cancer

The local and systemic antitumor efficacy of T-VEC as monotherapy for inoperable locoregional recurrence of breast cancer with or without distant metastases was explored in this study.

Scientific Reports
PD-L1 Expression on Circulating Tumor Cells and Platelets in Patients With Metastatic Breast Cancer

Researchers conducted a prospective preliminary study to determine the incidence of these findings in patients with metastatic breast cancer.

Validity of Breast Cancer Surgery Treatment Information in a State-Based Cancer Registry

Surgical treatment information contained in a statewide cancer registry with a focus on understanding the validity of this information for two critical populations is evaluated. 

Cancer Causes & Control
Most Women Face 6 to 22 Percent Risk of Breast Cancer Metastases

The risk of early breast cancer spreading to another part of the body ranges from 6 to 22 percent, according to research presented at the ABC6 International Consensus Conference. 

Cancer Therapy Advisor
Risk-Reducing Medications for Breast Cancer Are Becoming Safer and More Tolerable

Risk-reducing medications for breast cancer may be effective for many women as recently reported and studied in ongoing trials, leading to improvements in their tolerability and safety. 

The ASCO Post
Secreted Indicators of Androgen Receptor Activity in Breast Cancer Pre-Clinical Models

Researchers explore candidate serum factors that reflect tumor AR activity to support development of noninvasive serum biomarkers of AR activity in breast cancer.

Breast Cancer Research
Cis-Acting Super-Enhancer lncRNAs as Biomarkers to Early-Stage Breast Cancer

Cross-referencing SE-lncRNAs with patient samples in the TCGA database unveils 27 clinically relevant SE-lncRNAs that potentially interact with their enhancer to regulate nearby gene expression. 

Breast Cancer Research
Impact of Surgery on Survival in Breast Cancer With Bone Metastases Only

The impact of surgery on BC patients with bone metastases via a SEER database retrospective analysis was analyzed by researchers. 

BMC Surgery
Carboxypeptidase N1 is Anticipated to be a Synergy Metrics for Chemotherapy Effectiveness and Prognostic Significance in Invasive Breast Cancer

Researchers determine the potential role of Carboxypeptidase N1 in IBC tissues on chemotherapeutic efficacy and poor prognosis.

Cancer Cell International
Novel Temporal and Spatial Patterns of Metastatic Colonization From Breast Cancer Rapid-Autopsy Tumor Biopsies

Scientists collected 30 tumor samples over 3 timepoints, across 8 organs from a TNBC to comprehensively reconstruct the tumor’s evolution at subclonal resolution.

Genome Medicine
A Novel lncRNA ROPM-Mediated Lipid Metabolism Governs Breast Cancer Stem Cell Properties

This research highlights that lncROPM and its target PLA2G16 play crucial roles in sustaining BCSC properties and may serve as a biomarker for BCSCs or other cancer stem cells.

Journal of Hematology & Oncology
Oncogene-Mediated Metabolic Gene Signature Predicts Breast Cancer Outcome

Research demonstrates that the oncogene-mediated 5-gene metabolic signature is a powerful marker for aggressive breast cancer and a predictor for inferior breast cancer survival.

npj breast cancer
Ado-Trastuzumab for the Treatment of Metastatic HER2-Positive Breast Cancer in Patients Previously Treated With Pertuzumab

Researchers analyze the experience of patients treated with T-DM1 with and without prior treatment with pertuzumab for metastatic HER2-positive breast cancer.

BMC Cancer
Clinical Verification of Body Mass Index and Tumor Immune Response in Patients With Breast Cancer Receiving Preoperative Chemotherapy

Pretreatment BMI and TILs of breast cancer patients who underwent POC were measured and examined for correlations between the two factors then analyzed for their therapeutic outcomes and prognoses.

BMC Cancer
New Study to Develop Personalized Therapies for Triple-Negative Breast Cancer Patients

The PERSERVE trial aims to study personalized cancer treatment combinations when compared to standard cancer treatment to improve treatment options for patients with triple-negative breast cancer. 

Medical Xpress
IHC-based Ki67 as Response Biomarker to Tamoxifen in Breast Cancer Window Trials Enrolling Premenopausal Women

Pathologist assessed IHC-based Ki67 in samples from pre/postmenopausal women in a neo-adjuvant, endocrine therapy focused, randomized between tamoxifen, anastrozole, or fulvestrant were compared.

Breast Cancer
Extended Letrozole Prolonged Survival in Postmenopausal Patients With Breast Cancer

When compared with the standard 2-3 years of letrozole, 5 years of letrozole treatment improved both disease-free survival and overall survival.

Cancer Therapy Advisor
Defer Surgery in Operable Breast Cancer: How Long is Too Long?

Researchers evaluate outcomes of surgery compared to PET in patients with non-advanced, operable invasive breast cancer to determine if PET as initial therapy may safely postpone surgery.

Breast Cancer
ESMO Clinical Practice Guideline for the Diagnosis, Staging and Treatment of Patients With Metastatic Breast Cancer

This ESMO Clinical Practice Guideline provides key recommendations and algorithms for managing metastatic breast cancer.

Annals of Oncology
Imaging Characteristics of Young Age Breast Cancer (YABC) Focusing on Pathologic Correlation and Disease Recurrence

Researchers investigate imaging characteristics of young age breast cancer focusing on correlation with pathologic factors and association with disease recurrence.

Scientific Reports
Chronic Stress Hard on Women With Breast Cancer

Physiologic "wear and tear" from lifelong exposure to stressors was associated with a decreased likelihood of completing chemotherapy and a lower overall survival in breast cancer patients. 

Multi-Omics Data Integration Reveals Correlated Regulatory Features of Triple Negative Breast Cancer

Research highlights the diversity of the different TNBC subtypes, and sharpens our understanding of the molecular pathways that govern this challenging breast cancer.

Molecular Omics
Comparison of Two-View versus Single-View Digital Breast Tomosynthesis and 2D-Mammography in Breast Cancer Surveillance Imaging

The aim of this study was to investigate the differences between two different DBT implementations in breast cancer surveillance imaging, for patients with a personal history of breast cancer.

Clustering Subtypes of Breast Cancer by Combining Immunohistochemistry Profiles and Metabolism Characteristics Measured Using FDG PET/CT

The aim of this study was to investigate the effect of combining immunohistochemical profiles and metabolic information to characterize breast cancer subtypes.

Cancer Imaging
Comprehensive Analysis of the Cancer Driver Genes in Breast Cancer Demonstrates Their Roles in Cancer Prognosis and Tumor Microenvironment

The purpose of this study was to identify the expression characteristics and prognostic value of cancer driver genes in breast cancer.

World Journal of Surgical Oncology
Drug-Drug Interactions Between Palbociclib and Proton Pump Inhibitors May Significantly Affect Clinical Outcome of Metastatic Breast Cancer Patients

Re et al question the effect of co-administration of PPIs and palbociclib on progression-free survival (PFS) in metastatic breast cancer (mBC) patients.

Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-Risk Breast Cancer

Researchers study the pattern and prognosis for residual cancer burden after neoadjuvant chemotherapy in breast cancer patients. 

JAMA Oncology
Co-Expression and Prognosis Analyses of GLUT1–4 and RB1 in Breast Cancer

In this study, investigators analyze the co-expression of GLUT1–4 and the influence of GLUT1–4 gene expression on the prognosis of breast cancer.

BMC Cancer
Cost-Effectiveness of MR-Mammography in Breast Cancer Screening of Women With Extremely Dense Breasts After Two Rounds of Screening

This study evaluates the cost-effectiveness of MR-mammography vs. x-ray based mammography in two-yearly screening women of intermediate risk for breast cancer.

Frontiers in Oncology
Addition of Everolimus to Letrozole in Premenopausal Women With Advanced HR+, HER2- Breast Cancer

Fan et al find that the addition of everolimus to letrozole significantly improves PFS among premenopausal women with advanced HR+, HER2-breast cancer whose disease...

The ASCO Post

source list reference

rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb (245, 152, 2)
rgb(169, 196, 201)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rbg(16, 162, 230)
rgb(217, 7, 192)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)